跳至主要内容
临床试验/NCT05563870
NCT05563870已完成不适用

A Combined Endoscopy and Radiology-guided Radiofrequency Ablation Therapy Protocol for Inoperable Perihilar Cholangiocarcinoma

Clinical Hospital Colentina2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2022年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
26
试验地点
2
主要终点
Technical success of ERCP procedure

研究概览

简要总结

This prospective clinical trial aims to assess the feasibility, efficacy, and safety of a personalized radiofrequency ablation protocol coupled with complete biliary drainage for patients presenting with inoperable perihilar cholangiocarcinoma.

详细描述

This clinical trial proposes a personalized treatment approach to inoperable perihilar cholangiocarcinoma consisting of endoluminal ablative therapy via radiofrequency ablation followed by endoscopic biliary drainage.

Patients presenting with jaundice / biliary obstruction caused by inoperable perihilar cholangiocarcinoma as assessed during multidisciplinary case discussion will be invited to enroll in this trial.

Patients will be randomized in a 1:1 fashion to receive biliary plastic stenting (control arm) or biliary plastic stenting + radiofrequency ablation via endoscopic approach. In cases where ERCP fails to achieve adequate biliary drainage, stenting and/or drainage will be attempted via percutaneous approach.

Additional systemic chemotherapy will be offered to all eligible patients according to the local standard of care.

Patients will be followed up with a clinical visit at 2 weeks and stent exchange (+ additional RFA treatment in the control arm) will be offered at 8-12 weeks interval until disease progression, clinical deterioration precluding ERCP or death.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • perihilar cholangiocarcinoma
  • locally advanced disease (unresectable)
  • M1 (limted to 1 site)

排除标准

  • refusal to sogn the ICF
  • poor performance status (ECOG >2)
  • surgically altered anatomy (i.e Bilroth II or Roux-en-Y interventions)
  • significant comorbidities
  • ASA score >3
  • life expectancy <3 months

研究组 & 干预措施

COMBO-RFA Arm

Experimental

Patients randomized to this arm will undergo same-session endoluminal radiofrequency ablation followed by biliary stenting

干预措施: Endoluminal radiofrequency ablation (Procedure)

COMBO-RFA Arm

Experimental

Patients randomized to this arm will undergo same-session endoluminal radiofrequency ablation followed by biliary stenting

干预措施: Endoscopic biliary stenting (Procedure)

Endoscopic Drainage Arm

Active Comparator

Patients randomized to this arm will undergo biliary stenting only

干预措施: Endoscopic biliary stenting (Procedure)

结局指标

主要结局

Technical success of ERCP procedure

时间窗: 2 months

Ability to correctly apply radiofrequency ablation and place stents in all the biliary ducts accessed on ERCP

Tumor response

时间窗: 6 months

To evaluate the efficacy of radiofrequency ablation in local disease control by assessing tumor response according to RECIST criteria at 6 months follow-up

次要结局

  • Rate of procedure-related adverse events(12 months)
  • Overall survival(12 months)
  • Tumor microenvironment alterations(2 months)

研究者

发起方
Clinical Hospital Colentina
申办方类型
Other
责任方
Principal Investigator
主要研究者

dr. Theodor Alexandru Voiosu

Gastroenterology Consultant

Clinical Hospital Colentina

研究点 (2)

Loading locations...

相似试验